The need for a global HIV vaccine enterprise

Science

Volumn 300, Issue 5628, 2003, Pages 2036-2039

  Klausner, Richard D ^a   Fauci, Anthony S ^b   Corey, Lawrence ^d   Nabel, Gary J ^b   Gayle, Helene ^a   Berkley, Seth ^e   Haynes, Barton F ^f   Baltimore, David ^g   Collins, Chris ^h   Gordon Douglas, R ⁱ   Esparza, Jose ^j   Francis, Donald P ^k   Ganguly, N K ^l   Gerberding, Julie Louise ^m   Johnston, Margaret I ^c   Kazatchkine, Michel D ⁿ   McMichael, Andrew J ^o   Makgoba, Malegapuru W ^p   Pantaleo, Giuseppe ^q   Piot, Peter ^j   Shao, Yiming ^r   Tramont, Edmund ^b   Varmus, Harold ^s   Wasserheit, Judith N ^d   more..

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c DAIDS Epidemiology   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^h AIDS Vaccine Advocacy Coalition   (United States)

ⁱ Sequella Global Tuberculosis Found   (United States)

^j UNAIDS   (Switzerland)

^k VaxGen Inc   (United States)

^l INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^m CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁿ Agence Natl de Rech Sur le SIDA   (France)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF KWAZULU NATAL   (South Africa)

^q LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^r CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL LABORATORY; CLINICAL RESEARCH; DRUG MANUFACTURE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION; ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG DESIGN; DRUG INDUSTRY; DRUG SCREENING; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH; IMMUNOLOGY; INTERNATIONAL COOPERATION; MULTICENTER STUDY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATENT; POLICY; STANDARD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ACADEMIES AND INSTITUTES; AIDS VACCINES; BIOTECHNOLOGY; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; FINANCIAL SUPPORT; HIV INFECTIONS; HIV-1; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; MULTICENTER STUDIES; PRIVATE SECTOR; PUBLIC POLICY; PUBLIC SECTOR; RESEARCH SUPPORT; VACCINATION; WORLD HEALTH;

EID: 0038270791     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1086916     Document Type: Review

References (4)

1. J. Stover et al., Lancet 360, 73 (2002).
2. D. P. Francis, personal communication.
3. See www.hvtn.org
4. See www.iavi.org